| ||||||||||||||||||
Type Congenic; Mutant Strain; Transgenic; Additional information on Genetically Engineered and Mutant Mice. Visit our online Nomenclature tutorial. Additional information on Congenic nomenclature. Mating System Inbred x Hemizygote (Female x Male) 26-OCT-06 Species laboratory mouse Generation N12+3 (03-JUN-07) Donating Investigator Lennart Mucke, Gladstone Inst of Neurological Disease Description
These transgenic mice express a mutant form of the human amyloid protein precursor bearing both the Swedish (K670N/M671L) and the Indiana (V717F) mutations (APPSwInd). Expression of the transgenic insert is directed by the human platelet-derived growth factor beta polypeptide (PDGFB) promoter. Hemizygotes express immunodetectable transgene product in cerebral neurons, with the highest level of expression occurring in the neocortex and hippocampus. Enzyme-linked immunosorbent assay (ELISA) analysis reveals approximate total amyloid beta peptides and 42 amino acid length amyloid beta peptides in neocortical and hippocampal tissue from mutant mice. At five to seven months of age diffuse amyloid beta peptides deposition in the dendate gyrus and neocortex forms. Amyloid deposition is progressive with all transgenic mice exhibiting plaques by age eight to 10 months. This mutant mouse strain represents a model that may be useful in studies of the pathogenesis of Familial Alzheimer's Disease and possible therapeutic treatments.Development
A transgenic construct containing the mutant human amyloid protein precursor APPSwInd under the control of human platelet-derived growth factor beta polypeptide, simian sarcoma viral (v-sis) oncogene homolog, (PDGFB) promoter, was injected into C57BL/6 X DBA/2 F2 one-cell embryos. Heterozygous founder animals were bred to C57BL/6 X DBA/2 F1 mice. The resulting transgenic mice were then backcrossed for 12 generations on the C57BL/6J background.This strain was previously distributed as Stock No. 004661. That strain was found to have undergone a loss of transgenic copy number and consequent delayed onset of the phenotype, so this strain was re-imported from the lab of Dr. Lennart Mucke. Transgenic copy number is assayed using a Multiplex TaqMan assay.
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
Strains carrying other alleles of APP
008609 129S1.129(Cg)-Tg(APPSw)40Btla/2J 006409 129S1.129(Cg)-Tg(APPSw)40Btla/J 006555 A.129(B6)-Tg(APPSw)40Btla/J 005300 B6.129-Tg(APPSw)40Btla/J 005301 B6.129S2-Tg(APP)8.9Btla/J 006406 B6.129S4-Tg(APPSwLon)96Btla/J 009126 B6.Cg-Nos2tm1Lau Tg(Thy1-APPSwDutIowa)BWevn/J 005864 B6.Cg-Tg(APPswe,PSEN1dE9)85Dbo/J 004662 B6.Cg-Tg(PDGFB-APP)5Lms/J 006006 B6.Cg-Tg(Prnp-APP)A-2Dbo/J 006005 B6.Cg-Tg(Prnp-App/APPswe)E1-2Dbo/J 007049 B6.Cg-Tg(tetO-APPSwInd)885Dbo/J 004462 B6C3-Tg(APPswe,PSEN1dE9)85Dbo/J 006004 B6C3-Tg(tetO-APPSwInd)885Dbo/J 007027 C57BL/6-Tg(Thy1-APPSwDutIowa)BWevn/J 006472 D2.129(B6)-Tg(APPSw)40Btla/J View Strains carrying other alleles of APP (16 strains)
Strains carrying other alleles of PDGFB
004662 B6.Cg-Tg(PDGFB-APP)5Lms/J View Strains carrying other alleles of PDGFB (1 strain)
Visit the Alzheimer's Disease Mouse Model Resource site for helpful information on Alzheimer's Disease and research resources.
View Related Disease (OMIM) Terms
View Mammalian Phenotype Terms
Mammalian Phenotype Terms
assigned by genotype
Tg(PDGFB-APPSwInd)20Lms/0
B6.D2-Tg(PDGFB-APPSwInd)20Lms
- nervous system phenotype
- abnormal neuron morphology (MGI Ref ID J:100954)
- dystrophic neurites are associated with plaques
- amyloid beta deposits (MGI Ref ID J:100954)
- mice develop amyloid peptide deposits by 5-7 months of age
- other phenotype
- amyloid beta deposits (MGI Ref ID J:100954)
- mice develop amyloid peptide deposits by 5-7 months of age
Tg(PDGFB-APPSwInd)20Lms/0
B6.Cg-Tg(PDGFB-APPSwInd)20Lms
- nervous system phenotype
- abnormal pyramidal neuron morphology (MGI Ref ID J:118589)
- at 6 months and 12 to 16 months of age, 30% fewer pyramidal cells in the entorhinal cortex express Reelin than in wild-type mice
- however, no neuron loss is observed
The following phenotype information may relate to a genetic background differing from this JAX® Mice strain.
Tg(PDGFB-APPSwInd)20Lms/0
involves: C57BL/6 * DBA/2
- life span-post-weaning/aging
- premature death (MGI Ref ID J:141084)
- mice show premature death of unclear etiology with >15% mortality exhibited by 6 months, compared to all other genotypes
- high rate of premature (6 months or earlier) death
- behavior/neurological phenotype
- abnormal long term object recognition memory (MGI Ref ID J:121330)
- at 4-7 months of age, mice transgenic mice with wild-type Mapt expression take longer to locate the platform in the cued version of the Morris water maze test compared to transgenic mice heterozygous or homozygous for Mapt deletion
- abnormal spatial learning (MGI Ref ID J:121330)
- in the hidden platform version of the Morris water maze, non-trangenic controls, regardless of Mapt genotype learn the task over 3 days, whereas transgenic mice with wild-type expression of Mapt show no evidence of learning
- in probe trials where the platform is removed, mice show no learning, displaying no significantly elevated crossings of the target quadrant after 5 days of training
- in a Morris water maze, mice fail to favor the target platform location unlike wild-type mice
- decreased anxiety-related response (MGI Ref ID J:141084)
- mice exhibit disinhibition-like behaviors in an elevated plus maze compared with wild-type mice
- hyperactivity (MGI Ref ID J:141084)
- mice show hyperactivity in the Y-maze, a new cage, and elevated-plus maze compared to other transgenic mice or non-transgenic controls; this persists in mice 12-16 months of age
- increased susceptibility to pharmacologically induced seizures (MGI Ref ID J:121330)
- mice are abnormally sensitive to pentylenetetrazole (PTZ)-induced seizures with 20% suffering fatal status epilepticus at a PTZ dose not lethal in non-transgenic controls
- nervous system phenotype
- abnormal neurogenesis (MGI Ref ID J:121330)
- aberrant sprouting of hippocampal axons is observed in transgenic mice
- abnormal neuron morphology (MGI Ref ID J:121330)
- mice show neuritic dystrophy around amyloid plaques
- amyloid beta deposits (MGI Ref ID J:62290)
- diffuse immunoreactive amyloid deposits detected in dentate gyrus and neocortex of mice aged 5 to 7 months old
- all mice exhibit plaques by age 8 to 10 months
- at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics heterozygous null for Mapt
- soluble and insoluble Abeta-40 and -42 peptide deposits at 6-10 months
- increased susceptibility to pharmacologically induced seizures (MGI Ref ID J:121330)
- mice are abnormally sensitive to pentylenetetrazole (PTZ)-induced seizures with 20% suffering fatal status epilepticus at a PTZ dose not lethal in non-transgenic controls
- neurodegeneration (MGI Ref ID J:62290)
- neurodegeneration is indicated by an age dependent decrease in density of synaptophysin-immunoreactive presynaptic terminals
- other phenotype
- amyloid beta deposits (MGI Ref ID J:62290)
- diffuse immunoreactive amyloid deposits detected in dentate gyrus and neocortex of mice aged 5 to 7 months old
- all mice exhibit plaques by age 8 to 10 months
- at 4-7 months and 14-18 months, Abeta plaque deposition is observed, at levels the same as other transgenics heterozygous null for Mapt
- soluble and insoluble Abeta-40 and -42 peptide deposits at 6-10 months
View Research Applications
Research Applications
This mouse can be used to support research in many areas including:
APP relatedMouse/Human Gene Homologs
Alzheimer's
Neurobiology Research
Alzheimer's Disease
strains expressing mutant APP
Behavioral and Learning Defects
Tg(PDGFB-APPSwInd)20Lms relatedMouse/Human Gene Homologs
Alzheimer's
Neurobiology Research
Neurodegeneration
Neurobiology Research
Alzheimer's Disease
| Allele Symbol | Tg(PDGFB-APPSwInd)20Lms | ||
|---|---|---|---|
| Allele Name | transgene insertion 20, Lennart Mucke | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | APP Tg; J20; PDGF-APPSwInd; PDGF-hAPP695,751,770V171F, KM670/671NL; | ||
| Mutation Made By | Lennart Mucke, Gladstone Inst of Neurological Disease | ||
| Strain of Origin | (C57BL/6 x DBA/2)F2 | ||
| Expressed Gene | APP, amyloid beta (A4) precursor protein, human | ||
| Promoter | PDGFB, platelet-derived growth factor beta polypeptide (simian sarcoma viral (v-sis) oncogene homolog), human | ||
| General Note |
This line is also called line J20. Diffuse amyloid beta peptides deposition forms in the dendate gyrus and neocortex at 5 to 7 months of age. Amyloid deposition is progressive, with all transgenic mice exhibiting plaques by age 8 to 10 months. | ||
| Molecular Note | The transgene expresses the mutant human amyloid protein precursor APPSwInd, which bears both the Swedish (K670N/M671L) and the Indiana (V717F) mutations, under the control of the human platelet derived growth factor, B polypeptide (PDGFB) promoter. Hemizygous transgenic mice express immunodetectable transgene product in cerebral neurons, with the highest level of expression occurring in the neocortex and hippocampus. ELISA analysis reveals approximate total amyloid beta peptides and 42 amino acid lengthamyloid beta peptides in neocortical and hippocampal tissue from transgenic mice. [MGI Ref ID J:62290] | ||
Genotyping Protocols
Tg(APP), QPCR
Tg(PDGFB-APP), Melt Curve Analysis
Tg(PDGFB-APP), Melt Curve Analysis
Tg(PDGFB-APP), Standard PCR
Helpful Links
Genotyping resources and troubleshooting
Mucke L; Masliah E; Yu GQ; Mallory M; Rockenstein EM; Tatsuno G; Hu K; Kholodenko D; Johnson-Wood K; McConlogue L. 2000. High-level neuronal expression of abeta 1-42 in wild-type human amyloid protein precursor transgenic mice: synaptotoxicity without plaque formation. J Neurosci 20(11):4050-8. [PubMed: 10818140] [MGI Ref ID J:62290]
Moreno H; Wu WE; Lee T; Brickman A; Mayeux R; Brown TR; Small SA. 2007. Imaging the abeta-related neurotoxicity of Alzheimer disease. Arch Neurol 64(10):1467-77. [PubMed: 17923630] [MGI Ref ID J:125332]
Tg(PDGFB-APPSwInd)20Lms relatedAucoin JS; Jiang P; Aznavour N; Tong XK; Buttini M; Descarries L; Hamel E. 2005. Selective cholinergic denervation, independent from oxidative stress, in a mouse model of Alzheimer's disease. Neuroscience 132(1):73-86. [PubMed: 15780468] [MGI Ref ID J:97281]
Baron R; Harpaz I; Nemirovsky A; Cohen H; Monsonego A. 2007. Immunity and neuronal repair in the progression of Alzheimer's disease: a brief overview. Exp Gerontol 42(1-2):64-9. [PubMed: 17074458] [MGI Ref ID J:123181]
Baron R; Nemirovsky A; Harpaz I; Cohen H; Owens T; Monsonego A. 2008. IFN-gamma enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease. FASEB J 22(8):2843-52. [PubMed: 18390924] [MGI Ref ID J:138024]
Buckwalter MS; Coleman BS; Buttini M; Barbour R; Schenk D; Games D; Seubert P; Wyss-Coray T. 2006. Increased T cell recruitment to the CNS after amyloid beta 1-42 immunization in Alzheimer's mice overproducing transforming growth factor-beta 1. J Neurosci 26(44):11437-41. [PubMed: 17079673] [MGI Ref ID J:114703]
Caspersen C; Wang N; Yao J; Sosunov A; Chen X; Lustbader JW; Xu HW; Stern D; McKhann G; Yan SD. 2005. Mitochondrial Abeta: a potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19(14):2040-1. [PubMed: 16210396] [MGI Ref ID J:127883]
Cheng IH; Palop JJ; Esposito LA; Bien-Ly N; Yan F; Mucke L. 2004. Aggressive amyloidosis in mice expressing human amyloid peptides with the Arctic mutation. Nat Med 10(11):1190-2. [PubMed: 15502844] [MGI Ref ID J:100954]
Cheng IH; Scearce-Levie K; Legleiter J; Palop JJ; Gerstein H; Bien-Ly N; Puolivali J; Lesne S; Ashe KH; Muchowski PJ; Mucke L. 2007. Accelerating amyloid-beta fibrillization reduces oligomer levels and functional deficits in Alzheimer disease mouse models. J Biol Chem 282(33):23818-28. [PubMed: 17548355] [MGI Ref ID J:124712]
Cheng JS; Dubal DB; Kim DH; Legleiter J; Cheng IH; Yu GQ; Tesseur I; Wyss-Coray T; Bonaldo P; Mucke L. 2009. Collagen VI protects neurons against Abeta toxicity. Nat Neurosci 12(2):119-21. [PubMed: 19122666] [MGI Ref ID J:145982]
Chin J; Massaro CM; Palop JJ; Thwin MT; Yu GQ; Bien-Ly N; Bender A; Mucke L. 2007. Reelin depletion in the Enthorhinal cortex of human amyloid precursor protein transgenic mice and humans with Alzheimer's disease J Neurosci 27(11):2727-2733. [PubMed: 17360894] [MGI Ref ID J:118589]
Chin J; Palop JJ; Puolivali J; Massaro C; Bien-Ly N; Gerstein H; Scearce-Levie K; Masliah E; Mucke L. 2005. Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 25(42):9694-703. [PubMed: 16237174] [MGI Ref ID J:102161]
Chin J; Palop JJ; Yu GQ; Kojima N; Masliah E; Mucke L. 2004. Fyn kinase modulates synaptotoxicity, but not aberrant sprouting, in human amyloid precursor protein transgenic mice. J Neurosci 24(19):4692-7. [PubMed: 15140940] [MGI Ref ID J:96892]
Deipolyi AR; Fang S; Palop JJ; Yu GQ; Wang X; Mucke L. 2008. Altered navigational strategy use and visuospatial deficits in hAPP transgenic mice. Neurobiol Aging 29(2):253-66. [PubMed: 17126954] [MGI Ref ID J:130693]
Escribano L; Simon AM; Perez-Mediavilla A; Salazar-Colocho P; Del Rio J; Frechilla D. 2009. Rosiglitazone reverses memory decline and hippocampal glucocorticoid receptor down-regulation in an Alzheimer's disease mouse model. Biochem Biophys Res Commun 379(2):406-10. [PubMed: 19109927] [MGI Ref ID J:144519]
Esposito L; Raber J; Kekonius L; Yan F; Yu GQ; Bien-Ly N; Puolivali J; Scearce-Levie K; Masliah E; Mucke L. 2006. Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice. J Neurosci 26(19):5167-79. [PubMed: 16687508] [MGI Ref ID J:108685]
Gultner S; Laue M; Riemer C; Heise I; Baier M. 2009. Prion disease development in slow Wallerian degeneration (Wld(S)) mice. Neurosci Lett 456(2):93-8. [PubMed: 19429141] [MGI Ref ID J:150443]
Ho A; Liu X; Sudhof TC. 2008. Deletion of Mint proteins decreases amyloid production in transgenic mouse models of Alzheimer's disease. J Neurosci 28(53):14392-400. [PubMed: 19118172] [MGI Ref ID J:142874]
Hook VY; Kindy M; Reinheckel T; Peters C; Hook G. 2009. Genetic cathepsin B deficiency reduces beta-amyloid in transgenic mice expressing human wild-type amyloid precursor protein. Biochem Biophys Res Commun 386(2):284-8. [PubMed: 19501042] [MGI Ref ID J:151423]
Kalinin S; Gavrilyuk V; Polak PE; Vasser R; Zhao J; Heneka MT; Feinstein DL. 2007. Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimer's disease. Neurobiol Aging 28(8):1206-14. [PubMed: 16837104] [MGI Ref ID J:123899]
Leissring MA; Farris W; Chang AY; Walsh DM; Wu X; Sun X; Frosch MP; Selkoe DJ. 2003. Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation, secondary pathology, and premature death. Neuron 40(6):1087-93. [PubMed: 14687544] [MGI Ref ID J:87150]
Maier M; Peng Y; Jiang L; Seabrook TJ; Carroll MC; Lemere CA. 2008. Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice. J Neurosci 28(25):6333-41. [PubMed: 18562603] [MGI Ref ID J:135902]
Meilandt WJ ; Cisse M ; Ho K ; Wu T ; Esposito LA ; Scearce-Levie K ; Cheng IH ; Yu GQ ; Mucke L. 2009. Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci 29(7):1977-86. [PubMed: 19228952] [MGI Ref ID J:146594]
Meilandt WJ; Yu GQ; Chin J; Roberson ED; Palop JJ; Wu T; Scearce-Levie K; Mucke L. 2008. Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci 28(19):5007-17. [PubMed: 18463254] [MGI Ref ID J:135174]
Monsonego A; Imitola J; Petrovic S; Zota V; Nemirovsky A; Baron R; Fisher Y; Owens T; Weiner HL. 2006. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 103(13):5048-53. [PubMed: 16549802] [MGI Ref ID J:107636]
Moreno H; Wu WE; Lee T; Brickman A; Mayeux R; Brown TR; Small SA. 2007. Imaging the abeta-related neurotoxicity of Alzheimer disease. Arch Neurol 64(10):1467-77. [PubMed: 17923630] [MGI Ref ID J:125332]
Mueller-Steiner S; Zhou Y; Arai H; Roberson ED; Sun B; Chen J; Wang X; Yu G; Esposito L; Mucke L; Gan L. 2006. Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer's disease. Neuron 51(6):703-14. [PubMed: 16982417] [MGI Ref ID J:113649]
Palop JJ; Chin J; Roberson ED; Wang J; Thwin MT; Bien-Ly N; Yoo J; Ho KO; Yu GQ; Kreitzer A; Finkbeiner S; Noebels JL; Mucke L. 2007. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 55(5):697-711. [PubMed: 17785178] [MGI Ref ID J:126808]
Palop JJ; Jones B; Kekonius L; Chin J; Yu GQ; Raber J; Masliah E; Mucke L. 2003. Neuronal depletion of calcium-dependent proteins in the dentate gyrus is tightly linked to Alzheimer's disease-related cognitive deficits. Proc Natl Acad Sci U S A 100(16):9572-7. [PubMed: 12881482] [MGI Ref ID J:106227]
Pickford F; Masliah E; Britschgi M; Lucin K; Narasimhan R; Jaeger PA; Small S; Spencer B; Rockenstein E; Levine B; Wyss-Coray T. 2008. The autophagy-related protein beclin 1 shows reduced expression in early Alzheimer disease and regulates amyloid beta accumulation in mice. J Clin Invest 118(6):2190-9. [PubMed: 18497889] [MGI Ref ID J:137727]
Poirier R; Wolfer DP; Welzl H; Tracy J; Galsworthy MJ; Nitsch RM; Mohajeri MH. 2006. Neuronal neprilysin overexpression is associated with attenuation of Abeta-related spatial memory deficit. Neurobiol Dis 24(3):475-83. [PubMed: 17008108] [MGI Ref ID J:147325]
Roberson ED; Scearce-Levie K; Palop JJ; Yan F; Cheng IH; Wu T; Gerstein H; Yu GQ; Mucke L. 2007. Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science 316(5825):750-4. [PubMed: 17478722] [MGI Ref ID J:121330]
Sabbagh MN; Walker DG; Reid RT; Stadnick T; Anand K; Lue LF. 2008. Absence of effect of chronic nicotine administration on amyloid beta peptide levels in transgenic mice overexpressing mutated human APP (Sw, Ind). Neurosci Lett 448(2):217-20. [PubMed: 18926877] [MGI Ref ID J:143592]
Sanchez-Mejia RO; Newman JW; Toh S; Yu GQ; Zhou Y; Halabisky B; Cisse M; Scearce-Levie K; Cheng IH; Gan L; Palop JJ; Bonventre JV; Mucke L. 2008. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11(11):1311-8. [PubMed: 18931664] [MGI Ref ID J:141084]
Saura CA; Chen G; Malkani S; Choi SY; Takahashi RH; Zhang D; Gouras GK; Kirkwood A; Morris RG; Shen J. 2005. Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice. J Neurosci 25(29):6755-64. [PubMed: 16033885] [MGI Ref ID J:99847]
Serneels L; Van Biervliet J; Craessaerts K; Dejaegere T; Horre K; Van Houtvin T; Esselmann H; Paul S; Schafer MK; Berezovska O; Hyman BT; Sprangers B; Sciot R; Moons L; Jucker M; Yang Z; May PC; Karran E; Wiltfang J; D'Hooge R; De Strooper B. 2009. gamma-Secretase heterogeneity in the Aph1 subunit: relevance for Alzheimer's disease. Science 324(5927):639-42. [PubMed: 19299585] [MGI Ref ID J:147990]
Simon AM; Schiapparelli L; Salazar-Colocho P; Cuadrado-Tejedor M; Escribano L; Lopez de Maturana R; Del Rio J; Perez-Mediavilla A; Frechilla D. 2009. Overexpression of wild-type human APP in mice causes cognitive deficits and pathological features unrelated to Abeta levels. Neurobiol Dis 33(3):369-78. [PubMed: 19101630] [MGI Ref ID J:146301]
Sun B; Zhou Y; Halabisky B; Lo I; Cho SH; Mueller-Steiner S; Devidze N; Wang X; Grubb A; Gan L. 2008. Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer's disease. Neuron 60(2):247-57. [PubMed: 18957217] [MGI Ref ID J:144067]
Takuma K; Yao J; Huang J; Xu H; Chen X; Luddy J; Trillat AC; Stern DM; Arancio O; Yan SS. 2005. ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction. FASEB J 19(6):597-8. [PubMed: 15665036] [MGI Ref ID J:128890]
Tesseur I; Zou K; Esposito L; Bard F; Berber E; Can JV; Lin AH; Crews L; Tremblay P; Mathews P; Mucke L; Masliah E; Wyss-Coray T. 2006. Deficiency in neuronal TGF-beta signaling promotes neurodegeneration and Alzheimer's pathology. J Clin Invest 116(11):3060-9. [PubMed: 17080199] [MGI Ref ID J:114572]
Wyss-Coray T; Yan F; Lin AH; Lambris JD; Alexander JJ; Quigg RJ; Masliah E. 2002. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A 99(16):10837-42. [PubMed: 12119423] [MGI Ref ID J:78358]
Yao J; Taylor M; Davey F; Ren Y; Aiton J; Coote P; Fang F; Chen JX; Yan SD; Gunn-Moore FJ. 2007. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol Cell Neurosci 35(2):377-82. [PubMed: 17490890] [MGI Ref ID J:123215]
Yu H; Saura CA; Choi S; Sun LD; Yang X; Handler M; Kawarabayashi T; Younkin L; Fedeles B; Wilson MA; Younkin S; Kandel ER; Kirkwood A; Shen J. 2001. App processing and synaptic plasticity in presenilin-1 conditional knockout mice. Neuron 31(5):713-26. [PubMed: 11567612] [MGI Ref ID J:71606]
Zhang J; Gorostiza OF; Tang H; Bredesen DE; Galvan V. 2010. Reversal of learning deficits in hAPP transgenic mice carrying a mutation at Asp664: a role for early experience. Behav Brain Res 206(2):202-7. [PubMed: 19751769] [MGI Ref ID J:153969]
Animal Health Reports
Room Number AX11
Colony Maintenance
Breeding & Husbandry When maintaining a live colony, hemizygous males are bred to wildtype siblings or to C57BL/6J inbred females. Pups born of carrier females have shown an increased mortality rate in our colonies. Mating System Inbred x Hemizygote (Female x Male) 26-OCT-06 Diet Information LabDiet® 5K52/5K67
| Pricing for USA, Canada and Mexico shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $243.50 Female or Male Hemizygous for Tg(PDGFB-APPSwInd)20Lms
Weeks of Age Price (US dollars $) Genotype(s) Provided Price 6 months (never bred) $315.80 Hemizygous for Tg(PDGFB-APPSwInd)20Lms
Pairs /Price (US dollars $) Pair Genotype $261.25 C57BL/6J (000664) x Hemizygous for Tg(PDGFB-APPSwInd)20Lms $259.80 Hemizygous for Tg(PDGFB-APPSwInd)20Lms x C57BL/6J (000664)
| Pricing for International shipping destinations |
|
Weeks of Age Price (US dollars $) Gender Genotypes Provided Individual Mouse $316.60 Female or Male Hemizygous for Tg(PDGFB-APPSwInd)20Lms
Weeks of Age Price (US dollars $) Genotype(s) Provided Price 6 months (never bred) $410.60 Hemizygous for Tg(PDGFB-APPSwInd)20Lms
Pairs /Price (US dollars $) Pair Genotype $339.70 C57BL/6J (000664) x Hemizygous for Tg(PDGFB-APPSwInd)20Lms $337.80 Hemizygous for Tg(PDGFB-APPSwInd)20Lms x C57BL/6J (000664)
| Standard Supply | Repository-Live. A collection of over 1000 strains maintained as live colonies. Individual colonies are sized to meet current customer demand. Delivery for orders of 10 mice or less ranges on average from one to eight weeks; mice are generally shipped between four to six weeks of age with a maximum shipping age of approximately nine weeks. Colony sizes do not generally support stringent age specifications for large volumes of mice; however custom orders and larger quantities of mice are easily arranged. Estimated ship dates for all orders provided within two business days following order placement. |
|---|---|
| Supply Notes |
|
| Control | ||
|---|---|---|
| 000664 C57BL/6J | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 1-800-422-6423 or 1-207-288-5845
Fax: 1-207-288-6150
Technical Support Email Form
For Licensing and Use Restrictions view the link(s) below:
- Use of MICE only available to non-profit entities.
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of mice, products or services, JACKSON will, at its option, provide credit or replacement for the mice or product received or the services provided.
In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. In purchasing or receiving MICE, PRODUCTS or services from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.
MICE and PRODUCTS are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or services. In addition, special terms and conditions of sale of certain MICE, PRODUCTS or services may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and services by JACKSON, and by its licensees and distributors.
Acceptance of delivery of MICE, PRODUCTS or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or services by JACKSON.